Abstract: PO0963
Thirty Days of Maintenance Peritoneal Dialysis Using a Sorbent-Based Automated Wearable Artificial Kidney (AWAK) PD Device in a Porcine Model
Session Information
- Home Dialysis: Disparities and Modality Choice
November 04, 2021 | Location: On-Demand, Virtual Only
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 702 Dialysis: Home Dialysis and Peritoneal Dialysis
Authors
- Foo, Marjorie Wai Yin, Singapore General Hospital, Singapore, Singapore
- Htay, Htay, Singapore General Hospital, Singapore, Singapore
- Brown, Edwina A., Hammersmith Hospital, London, London, United Kingdom
- Chirumarry, Sridhar, AWAK Technologies Pte Ltd, Singapore, Singapore
- Pawlak, Marcin, AWAK Technologies Pte Ltd, Singapore, Singapore
- Huda, Siti Noor, AWAK Technologies Pte Ltd, Singapore, Singapore
- Lim, Jason Tze chern, AWAK Technologies Pte Ltd, Singapore, Singapore
- Singh, Sanjay, AWAK Technologies Pte Ltd, Singapore, Singapore
- Gori, Mandar, AWAK Technologies Pte Ltd, Singapore, Singapore
- Venkataraya, Suresha Belur, AWAK Technologies Pte Ltd, Singapore, Singapore
- Jain, Arsh, Western University, London, Ontario, Canada
Background
In sorbent-based PD, spent dialysate is processed and clean dialysate is re-introduced into the abdomen. Our aim was to determine if AWAK dialysis can maintain euvolemia and biochemistry for 30 days in a porcine model.
Methods
The study was conducted in a 5/6 nephrectomised pig (Sus Scrofa, male). Post nephrectomy, the animal was treated with CAPD (14 weeks) before commencing sorbent-based PD for 7 hour per day with initial fill of 2L 1.5% Dianeal for 30 consecutive days. Thereafter, the animal was maintained on standard of care (SOC) for 3 days (5x2L exchanges over 10 hour APD, with 1L last fill, 2.5% Dianeal).
Results
Stable serum concentration of toxins, electrolytes and inflammatory markers were noted during AWAK therapy (Table); with no significant change after switch to SOC. pH of regenerated dialysate was consistent with biocompatible solutions (figure 1) and appropriate change in ultrafiltration was observed in response to glucose infusion (figure 2).
Conclusion
AWAK PD therapy successfully treated a CKD animal model for 30 days, without adverse impact on volume status or clinical parameters. Future long-term human studies are needed for device enhancement.
| Day 1 [AWAK] | Day 30 [AWAK] | Mean (SD) [AWAK] | Median (IQR) [AWAK] | Mean (SD) [SOC] | p-value# | |
| Urea (mmol/L) | 7.5 | 7.9 | 8.5 (0.6) | 8.6 (1) | 8.9 (0.72) | 0.29 |
| Creatinine (μmol/L) | 267.5 | 287.5 | 282.5 (9.9) | 283 (14.4) | 296.6 (4.8) | 0.38 |
| Phosphate (mmol/L) | 2.57 | 2.72 | 2.6 (0.1) | 2.6 (0.2) | 2.6 (0.04) | 0.83 |
| B2M (μg/L) | 317.5 | 266.5 | 293.6 (17) | 297.5 (27.7) | 285.3 (15.0) | 0.24 |
| Sodium (mmol/L) | 142.5 | 145 | 144.6 (1.4) | 144.8(1.5) | 145.6 (1.52) | 0.87 |
| Potassium (mmol/L) | 4.4 | 4.8 | 4.6 (0.18) | 4.6 (0.36) | 4.8 (0.2) | 0.19 |
| Chloride (mmol/L) | 100 | 101 | 101.2 (1.0) | 101 (1.4) | 100.1 (0.2) | 0.01 |
| Bicarbonate (mmol/L) | 34.6 | 34.1 | 34 (1.0) | 34 (1.2) | 34.8 (1.55) | 0.97 |
| Calcium (mmol/L) | 2.41 | 2.45 | 2.4 (0.04) | 2.4 (0.1) | 2.47 (0.02) | 0.19 |
| Magnesium (mmol/L) | 1.09 | 1.13 | 1.1 (0.05) | 1.1 (0) | 1.14 (0.04) | 0.29 |
| CRP | 0.45 | 0.35 | 0.36 (0.08) | 0.4 (0.1) | 0.28 (0.05) | 0.25 |
| WBC (x10^9) g/L | 13.3 | 8.8 | 9.6 (1.7) | 9.4 (0.9) | 8.85 (0.20) | 0.84 |
| Hb (g/dL) | 8.4 | 11.4 | 10.7 (0.8) | 10.9 (1.0) | 11.2 (0.65) | 0.93 |
#last 3 days data of AWAK and SOC compared
Funding
- Commercial Support – AWAK Technologies Pte Ltd